| Symbol | XFOR |
|---|---|
| Name | X4 PHARMACEUTICALS, INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biological Products, (No Diagnostic Substances) |
| Address | 61 NORTH BEACON STREET, BOSTON, MA 02134 |
| Telephone | 857-529-8300 |
| Fax | — |
| — | |
| Website | https://www.x4pharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001501697 |
| Description | X4 Pharmaceuticals Inc is clinical-stage biopharmaceutical company. It is focused on restoring the immune system function by developing therapeutics for the treatment of rare diseases. Its molecule therapeutics are antagonists of chemokine receptor CXCR4, which have the potential to treat a broad range of rare diseases, including primary immunodeficiencies (PIs) and cancer. Its product candidate, X4P-001, has completed a Phase 2 trial in patients with a rare genetic PI called Warts. The company is also developing X4P-002, a CXCR4 antagonist that has properties that could enable penetration of the blood-brain barrier and provide appropriate therapeutic exposures to treat brain cancers, including glioblastoma multiforme. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - X4 Pharmaceuticals, Inc <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001193125-26-352651 <b>Size:</b> 11 KB
Read moreNew Form SCHEDULE 13G/A - X4 Pharmaceuticals, Inc <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001172661-26-003487 <b>Size:</b> 14 KB
Read more📋 John Volpone (Officer) plans to sell 25K shares of X4 Pharmaceuticals, Inc (at $4.55 each, total $112K) Filed: Aug 13, 2026 | ID: 000004
Read more📋 Adam Craig (Executive Chaiman) plans to sell 47K shares of X4 Pharmaceuticals, Inc (at $4.55 each, total $216K) Filed: Aug 13, 2026 | ID: 000003
Read moreX4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Read moreX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read moreX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read moreX4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors
Read moreX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read moreNew Form EFFECT - X4 Pharmaceuticals, Inc <b>Filed:</b> 2026-05-14 <b>AccNo:</b> 9999999995-26-001669 <b>Size:</b> 1 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06858696 | A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mav… | Phase1 | Hepatic Insufficiency | Completed | 2025-02-28 | 2026-01-12 | ClinicalTrials.gov |
| NCT06914869 | Drug-Drug Interaction Potential of Mavorixafor | Phase1 | Healthy Participants | Completed | 2025-02-18 | 2025-05-19 | ClinicalTrials.gov |
| NCT06056297 | A Study of Mavorixafor in Participants With Congenital and Acquired Primary Aut… | Phase3 | Neutropenia | Recruiting | 2024-06-06 | 2027-11-01 | ClinicalTrials.gov |
| NCT04154488 | A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic … | Phase1 | Neutropenia | Completed | 2021-10-16 | 2024-08-27 | ClinicalTrials.gov |
| NCT04274738 | A Study of Mavorixafor in Combination With Ibrutinib in Participants With Walde… | Phase1 | Waldenstrom's Macroglobulinemia | Completed | 2020-04-30 | 2022-10-31 | ClinicalTrials.gov |
| NCT03995108 | Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammag… | Phase3 | WHIM Syndrome | Completed | 2019-10-24 | 2025-12-23 | ClinicalTrials.gov |
| NCT03087370 | A Retrospective and Prospective Natural History Study of Patients With WHIM Syn… | — | WHIM Syndrome | Withdrawn | 2018-06-01 | 2022-03-01 | ClinicalTrials.gov |
| NCT02923531 | Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carc… | Phase1 | Clear Cell Renal Cell Carcinoma | Terminated | 2016-12-07 | 2018-08-08 | ClinicalTrials.gov |
| NCT03005327 | A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants … | Phase2 | WHIM Syndrome | Completed | 2016-12-01 | 2022-06-16 | ClinicalTrials.gov |
| NCT02823405 | X4P-001 and Pembrolizumab in Patients With Advanced Melanoma | Phase1 | Melanoma | Completed | 2016-09-15 | 2018-03-15 | ClinicalTrials.gov |
| NCT02667886 | Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma | Phase1 | Clear Cell Renal Cell Carcinoma | Completed | 2016-04-27 | 2022-04-14 | ClinicalTrials.gov |
| NCT02680782 | A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volun… | Phase1 | Healthy | Terminated | 2016-01-12 | 2016-02-28 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE3 | Neutropenia | RECRUITING | NCT06056297 |
| Mavorixafor | Other | Phase PHASE3 | Neutropenia | RECRUITING | NCT06056297 |
| Mavorixafor | Other | Phase PHASE1 | Hepatic Insufficiency | COMPLETED | NCT06858696 |
| Placebo | Other | Phase PHASE3 | WHIM Syndrome | COMPLETED | NCT03995108 |
| Mavorixafor | Other | Phase PHASE3 | WHIM Syndrome | COMPLETED | NCT03995108 |
| Placebo | Other | Phase PHASE3 | Neutropenia | RECRUITING | NCT06056297 |
| Mavorixafor | Other | Phase PHASE3 | Neutropenia | RECRUITING | NCT06056297 |
| No intervention | Other | Preclinical | WHIM Syndrome | WITHDRAWN | NCT03087370 |
| X4P-001 | Other | Phase PHASE1 | Healthy | TERMINATED | NCT02680782 |
| Pembrolizumab | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT02823405 |
| X4P-001 | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT02823405 |
| Nivolumab | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | TERMINATED | NCT02923531 |
| X4P-001 | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | TERMINATED | NCT02923531 |
| Ibrutinib | Other | Phase PHASE1 | Waldenstrom's Macroglobulinemia | COMPLETED | NCT04274738 |
| Mavorixafor | Other | Phase PHASE1 | Waldenstrom's Macroglobulinemia | COMPLETED | NCT04274738 |
| axitinib | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | COMPLETED | NCT02667886 |
| X4P-001 | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | COMPLETED | NCT02667886 |
| X4P-001 | Other | Phase PHASE2 | WHIM Syndrome | COMPLETED | NCT03005327 |
| Mavorixafor | Other | Phase PHASE1 | Hepatic Insufficiency | RECRUITING | NCT06858696 |
| Efavirenz | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06914869 |
| Carbamazepine | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06914869 |
| Mavorixafor | Other | Phase PHASE1 | Healthy Participants | COMPLETED | NCT06914869 |
| Placebo | Other | Phase PHASE3 | WHIM Syndrome | ACTIVE_NOT_RECRUITING | NCT03995108 |
| Mavorixafor | Other | Phase PHASE3 | WHIM Syndrome | ACTIVE_NOT_RECRUITING | NCT03995108 |
| Mavorixafor | Other | Phase PHASE1 | Neutropenia | COMPLETED | NCT04154488 |
| Placebo | Other | Phase PHASE3 | Neutropenia | RECRUITING | NCT06056297 |
| Mavorixafor | Other | Phase PHASE3 | Neutropenia | RECRUITING | NCT06056297 |
| placebo | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT01527734 |
| Nasulin | DRUG | Phase PHASE2 | Type 2 Diabetes | COMPLETED | NCT00850096 |
| Placebo for Nasulin | OTHER | Phase PHASE2 | Type 2 Diabetes | COMPLETED | NCT00850096 |
| Placebos | DRUG | Phase PHASE1 | TQT Study | COMPLETED | NCT04083833 |
| OLX10010 | DRUG | Phase PHASE1 | Cicatrix, Hypertrophic | COMPLETED | NCT03569267 |
| Tetrodotoxin | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT01527734 |
| Capecitabine | DRUG | Phase PHASE1 | Metastatic Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05249101 |
| Ivaltinostat | DRUG | Phase PHASE1 | Metastatic Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05249101 |
| OLX72021 | DRUG | Phase PHASE1 | Androgenetic Alopecia (AGA) | RECRUITING | NCT07327359 |
| Placebo | BIOLOGICAL | Phase PHASE3 | Pain | COMPLETED | NCT00725114 |